Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cytosorbents Corporation stock

Own Cytosorbents Corporation stock in just a few minutes.

Cytosorbents Corporation is a medical devices business based in the US. Cytosorbents Corporation shares (CTSO) are listed on the NASDAQ and all prices are listed in US Dollars. Cytosorbents Corporation employs 195 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Cytosorbents Corporation

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CTSO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cytosorbents Corporation share price

Use our graph to track the performance of CTSO stocks over time.

Cytosorbents Corporation shares at a glance

Information last updated 2021-04-30.
52-week range$7.13 - $11.74
50-day moving average $8.89
200-day moving average $8.99
Wall St. target price$14.88
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.53

Buy Cytosorbents Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Cytosorbents Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cytosorbents Corporation financials

Revenue TTM $41 million
Gross profit TTM $30 million
Return on assets TTM -11.05%
Return on equity TTM -18.97%
Profit margin -19.11%
Book value $1.83
Market capitalisation $394.2 million

TTM: trailing 12 months

Shorting Cytosorbents Corporation shares

There are currently 2.1 million Cytosorbents Corporation shares held short by investors – that's known as Cytosorbents Corporation's "short interest". This figure is 0.9% up from 2.1 million last month.

There are a few different ways that this level of interest in shorting Cytosorbents Corporation shares can be evaluated.

Cytosorbents Corporation's "short interest ratio" (SIR)

Cytosorbents Corporation's "short interest ratio" (SIR) is the quantity of Cytosorbents Corporation shares currently shorted divided by the average quantity of Cytosorbents Corporation shares traded daily (recently around 264777.11757269). Cytosorbents Corporation's SIR currently stands at 7.91. In other words for every 100,000 Cytosorbents Corporation shares traded daily on the market, roughly 7910 shares are currently held short.

However Cytosorbents Corporation's short interest can also be evaluated against the total number of Cytosorbents Corporation shares, or, against the total number of tradable Cytosorbents Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cytosorbents Corporation's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Cytosorbents Corporation shares in existence, roughly 50 shares are currently held short) or 0.0493% of the tradable shares (for every 100,000 tradable Cytosorbents Corporation shares, roughly 49 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cytosorbents Corporation.

Find out more about how you can short Cytosorbents Corporation stock.

Cytosorbents Corporation share dividends

We're not expecting Cytosorbents Corporation to pay a dividend over the next 12 months.

Have Cytosorbents Corporation's shares ever split?

Cytosorbents Corporation's shares were split on a 1:25 basis on 4 December 2014. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytosorbents Corporation shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Cytosorbents Corporation shares which in turn could have impacted Cytosorbents Corporation's share price.

Cytosorbents Corporation share price volatility

Over the last 12 months, Cytosorbents Corporation's shares have ranged in value from as little as $7.13 up to $11.74. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytosorbents Corporation's is 0.2532. This would suggest that Cytosorbents Corporation's shares are less volatile than average (for this exchange).

Cytosorbents Corporation overview

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintaining or improving the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, a device to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site